BioRestorative Therapies

BioRestorative Therapies EBIT Margin

The EBIT Margin (Operating Margin) of BioRestorative Therapies (BRTX) as of Nov 3, 2026 is -4,350.05 %. In the previous year, EBIT Margin (Operating Margin) was -2,881.59 % — a change of 50.96% (lower).

EBIT Margin

-4,350.05 %

YoY

50.96%

Last updated:

EBIT Margin (Operating Margin) of BioRestorative Therapies is 2025 -4,350.05 % . EBIT Margin (Operating Margin) of BioRestorative Therapies was 2024 -2,881.59 % . It decreases by 50.96% lower compared to the previous year.

BioRestorative Therapies's operating (EBIT) margin stands at -4,350.1%, up from -57,191.0% several years earlier.

The BioRestorative Therapies EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
-6,889.78 USD
Jan 1, 2019
-6,486.16 USD
Jan 1, 2020
-3,574.12 USD
Jan 1, 2021
-57,191.03 USD
Jan 1, 2022
-15,745.83 USD
Jan 1, 2023
-10,439.49 USD
Jan 1, 2024
-2,881.59 USD
Jan 1, 2025
-4,350.05 USD
The BioRestorative Therapies EBIT Margin history
YEAREBIT MarginYoY
-4,350.05 %+50.96%
-2,881.59 %-72.40%
-10,439.49 %-33.70%
-15,745.83 %-72.47%
-57,191.03 %+1,500.14%
-3,574.12 %-44.90%
-6,486.16 %-5.86%
-6,889.78 %-33.36%
-10,338.62 %-51.80%
-21,447.55 %+1,781.17%
-1,140.12 %-3.65%
-1,183.31 %-58.17%
-2,828.73 %+691.34%
-357.46 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

BioRestorative Therapies Stock analysis

What does BioRestorative Therapies do? BioRestorative Therapies Inc generates revenue through the development and commercialization of cell-based therapeutic products. The company focuses on two primary programs: the Disc/Spine Program (brtxDISC) and the Metabolic Program (ThermoStem). Its lead product, BRTX-100, is a cell therapy formulated from autologous cultured mesenchymal stem cells derived from patients' bone marrow, designed for non-surgical treatment of lumbosacral disc disorders. The company also develops ThermoStem, a therapy using brown adipose-derived stem cells to create brown adipose tissue for metabolic conditions like obesity and diabetes. BioRestorative Therapies targets medical professionals and healthcare institutions seeking innovative cell therapies for chronic conditions, with its products in development stages focused on specific therapeutic applications. The company’s revenue model relies on the future commercialization of BRTX-100 and ThermoStem, with no current sales reported. Its proprietary production process for BRTX-100 involves collecting bone marrow, isolating and culturing stem cells, and cryopreserving them. ThermoStem’s development targets metabolic disorders, leveraging the company’s expertise in cell and tissue protocols. BioRestorative Therapies Inc operates as a life sciences firm specializing in adult stem cell therapies, with its products positioned for potential market entry in the biotechnology sector. BioRestorative Therapies Inc’s business strategy centers on advancing its pipeline of cell-based therapies, including BRTX-100 for disc disorders and ThermoStem for metabolic conditions. The company’s focus on proprietary technology and cell culture methods differentiates its approach within the biotechnology industry. While currently in development, its products aim to address unmet medical needs, targeting healthcare providers and patients with chronic conditions requiring non-surgical interventions. BioRestorative Therapies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioRestorative Therapies stock

EBIT Margin (Operating Margin) of BioRestorative Therapies is -4,350.05 % in 2025.

EBIT Margin (Operating Margin) of BioRestorative Therapies changed from -2,881.59 % to -4,350.05 %, representing a 50.96% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) BioRestorative Therapies since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s BioRestorative Therapies with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — BioRestorative Therapies

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — BioRestorative Therapies